2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6107 Population-informed Bayesian inference of TPSAB1 copy number enables genome-first phenome-wide exploration in the NIH all of us cohort

Zhiyv Niu, PhD, FACMG, Milovan Suvakov, PhD2, Nipun Mistry, MS3, Jie Na, MS4, Xi Zhang, MD, PhD5, Alexej Abyzov, Phd6, Thanai Pongdee, MD7, Animesh Pardanani, PhD, MBBS8, Dong Chen, MD, PhD9
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States

Introduction:
The TPSAB1 tryptase gene family is copy-number variable, and high sequence homology across the locus presents challenges for accurate copy-number assessment using short-read sequencing. Increased copy number of alpha-tryptase–encoding TPSAB1 alleles underlies hereditary alpha-tryptasemia (HaT); however, gene-level TPSAB1 copy-number gain alone does not define alpha-tryptase dosage, and HaT is likely underrepresented in electronic health records (EHRs). We developed a stepwise, cloud-based bioinformatic pipeline for TPSAB1 copy-number and isoform inference and applied it to whole-genome sequencing (WGS) data linked to EHRs from the NIH All of Us Research Program.

Methods:
CNVpytor was used to derive normalized TPSAB1 read depth (RD) and B-allele-frequency deviation (dBAF). Copy-number states were assigned using a population-informed, seed-calibrated Bayesian RD model. Empirical RD thresholds were used as initial seeds, population frequencies informed prior probabilities, and posterior probabilities defined high-confidence copy number 2 (CN2) and copy number 3 (CN3) cohorts. dBAF patterns provided complementary support for selected calls. An isoform classifier incorporating alpha-, beta-, and delta-tryptase coverage ratios was used to estimate TPSAB1 dosage, which achieved 99.6% concordance with reference dataset common alpha/beta copy-number distribution. RD based TSPAB1 copy number showed close correlation with total alpha-, beta- isoform copy. Because explicit HaT diagnoses were expected to be sparse in current EMR, a phenotype discovery was performed as a phenome-wide association study (PheWAS) across EMR billing code mapped to phecodeX version. Logistic regression was used for exploratory CN3-versus-CN2 association testing, adjusting for standard covariates such as age, sex, and genetic ancestry principal components.

Results:
The initial RD based TPSAB1 screen was performed on NIH All of US v7 cohort of ~248,000 WGS samples and identified 14,183 putative CN3/gain calls with posterior probability >0.90. CN2 high confidence samples 211,070 serve as the control group. Evaluation across genetically inferred ancestry groups revealed variation in genotype distributions, suggesting population-specific patterns at the TPSAB1 locus. The initial PheWAS evaluated 3,488 phecodes (>2 EMR events) derived from 12,333,174 phecode records. PheWAS regression testing review phecodes as candidates including “Mast cell CA_120.15” [odds ratio OR 2.498; p=2.31×10?³), “Disease of capillaries CA_442” [OR 1.901309; p=0.90×10?6). Manual review of enriched diagnosis codes and molecular pathway analysis on mast cell biology are conducted as hypothesis-generating analysis.

Conclusions:
A population-informed, seed-calibrated Bayesian RD model, supported by dBAF, enables scalable TPSAB1 copy-number inference from population WGS data. Preliminary PheWAS demonstrates the feasibility of genome-first phenotype exploration at this complex locus but does not establish HaT or causal associations. Study limitations include the challenges of quality control in large-scale genomic datasets, which were addressed through statistical modeling but may still introduce residual uncertainty; the limited representation of HaT diagnoses in EHR data; and observed variation in genotype patterns across genetically inferred ancestry groups, which may expand our understanding on this gene family and phenotype spectrum.

Zhiyv Niu, PhD, FACMG: Genome Medical Inc and Sarepta - Consultancy (Includes expert testimony)